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Abstract
Background and Aim: We investigated the prognostic importance of dickkopf-1(DKK1) and beta-catenin expression in triple
negative breast cancers.
Methods: The expression of DKK1 and beta-catenin was evaluated in breast cell lines using RT-PCR and western blot.
Immunohistochemistry was used to characterize the expression pattern of DKK1 and beta-catenin in 85 triple negative
breast cancers and prognostic significance was assessed by Kaplan-Meier analysis and Cox proportional hazards regression
modeling.
Results: The expression of DKK1 was confirmed in hormone-resistant breast cell lines MDA-MB-231, MDA-MB-231-HM and
MDA-MB-435. Expression of DKK1 in triple negative breast cancers correlated with cytoplasmic/nuclear beta-catenin
(p=0.000). Elevated expression of DKK1 and cytoplasmic/nuclear beta-catenin in triple negative cancers indicate poor
outcome of patients. DKK1 was also a prognostic factor for patients with earlier stage or no lymph node metastasis.
Conclusion: DKK1 together with beta-catenin might be important prognostic factors in triple negative breast carcinoma.
DKK1 might be a valuable biomarker in predicting the prognosis of patients with earlier stage or no lymph node metastasis.
It is possible that through further understanding of the role of Wnt/beta-catenin pathway activation, beta-catenin would be
a potential therapeutic target for the triple negative breast cancer.
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Introduction
Breast cancer is a disease with heterogeneous nature and our
understanding of the breast subtypes had been previously based on
histopathology and immunohistochemical criteria. Over the last
decade, gene expressing studies with DNA microarrays have
identified four common subtypes of this disease. ER positive
tumors included luminal A and B tumors, while ER negative
tumors included basal-like and HER-2 positive tumors. Most of
the basal-like tumors, which also referred to as ‘‘triple-negative’’
breast cancers, are negative for ER, PR and HER2[1,2].
Women with triple-negative breast cancers are reported to have
an increased likelihood of distant recurrence and death than
women with other types of breast cancer within 5 years after
diagnosis but not there-after [3]. They also have been reported to
have a tendency toward visceral (versus bone) metastasis, local
relapse and cerebral metastases [4,5]. Since the usage of
trastuzumab and lapatinib, the recurrence and mortality rate of
HER2 positive patients has considerably reduced, which may
render the triple negative women at most risk of early recurrence.
The prognosis of breast cancer patients may be influenced by
traditional parameters, such as pathology type, lymph node status,
tumor size, stage and expression of hormone receptors. Yet
patients with the same parameters mentioned above may have
totally different prognosis. So biomarkers for the prediction of
prognosis are need in daily clinical practice.
The Wnt/beta-catenin pathway was implicated in mammary
tumorigenesis since over expression of wnt1 gene in the mammary
epithelium was identified sufficient for mammary gland hyperpla-
sia and adeno-carcinomas [6]. Binding to the frizzled receptor (Fz)
and the low-density lipoprotein receptor-related protein-5/
6(LRP5/6), Wnt-1 protein prevents phosphorylation and degra-
dation of beta-catenin by the GSK3b/APC/axin destruction
complex. Subsequently accumulated cytosolic and nuclear beta-
catenin bound to TCF transcription factors and resulted in
activating downstream signals which are important for prolifera-
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that deregulated beta-catenin signaling increases risk of breast
cancer by inducing stem cell and early progenitor cell accumu-
lation [8,9]. And one gene expression signature derived from
MMTV-Wnt1 tumor-initiating cells was found to have prognostic
value in basal-like and hormone receptor-negative cancers [10].
Several studies have reported increased cytoplasmic and nuclear
beta-catenin in primary breast cancers, especially basal-like breast
cancers, and correlated with poor prognosis and survival
[11,12,13].
DKK-1, a secreted protein involved in head formation in
embryonic development, binds to LRP5/6, blocks Wnt-1 protien
signaling and plays as an antagonist of Wnt signaling [14]. DKK1
has also been reported to be over expressed in many carcinomas
including lung cancer, esophageal squamous cell carcinoma,
hepatocellular carcinoma, Wilm’s tumor and multiple myeloma
[15,16,17,18]. These indicate that DKK1 performs as an
oncogenic factor rather than a tumor-suppressor in tumors. Forget
MA et al has reported expression of DKK1 in 21 out of 73 cases of
breast cancer patients, in particular hormone-resistant patients
[19]. These findings raise an intriguing possibility that DKK1 may
be involved in the prognosis in triple negative breast cancer. To
test this hypothesis, we investigated the expression of DKK1 and
beta-catenin in tumor specimens from 85 patients with breast
cancer and the correlation between DKK1 and beta-catenin
together with other clinical pathological features of prognosis in
this study.
Materials and Methods
Ethics
All samples were anonymously coded in accordance with local
ethical guidelines, and written informed consent was obtained.
This study was approved by the Review Board of Fudan
University Shanghai Cancer Center and conforms to the
principles outlined in the Declaration of Helsinki (IRB number:
050432-4-10087A).
Cell Lines
Human breast cancer cell lines MDA-MB-231, MCF7, BT-474,
SK-BR-3, MDA-MB-435, MCF10A and Hela cell were pur-
chased from the American Type Culture Collection. The highly
metastatic MDA-MB-231HM line, which has a high potential to
metastasize to the lung, was established by our institute [20].
Patients and Specimens
A total of 1614 different breast invasive carcinoma was
identified in the database of the Department of Breast Surgery
of the Cancer Hospital affiliated to Fudan University in the period
between 2000 and 2002. We targeted the 136 triple-negative (ER
negative, PR (progesterone receptor)-negative, HER-2 negative)
patients who were consecutively obtained from the 1614 cases with
operable breast cancer. They have been followed regularly, and 85
cases obtained the clinical outcome, with the last update in June
2011. The median follow up time was 80 months.
RT-PCR
Total RNA from cells was extracted using TRIzol regent (Gibco
Invitrogen, Carlsbad, CA, USA) following the manufacturer’s
instructions, converted to cDNA with RevertAid First Strand
cDNA Synthesis Kit (MBI Fermentas, Vilnius, Lithuania).
Classical RT-PCR amplification was undertaken with Taq DNA
Polymerase (MBI Fermentas, Vilnius, Lithuania). The primer
sequences for DKK1 were: forward AACGCTATCAA-
GAACCTGC and reverse GATGACCGGAGACAAACA result-
ing in 460-bp amplification. The primer sequences for GAPDH
were : forward GGGAGCCAAAAGGGTCATCATCTC and
reverse CCATGCCAGTGAGCTTCCCGTTC, resulting in a
353 bp amplification. The cycling conditions were 5 min at 94uC,
24 (GAPDH) or 35 (DKK1) cycles of 30 s at 94uC, 45 s at 52uC,
1 min at 72uC, with a final extension of 10 min at 72uC, in the
Eppendorf Mastercycler 22331 (Eppendorf, Hamburg, Germany).
Figure 1. The mRNA and protein expression of DKK1 in breast
cancer cell lines. A) The mRNA expression of DKK-1 in MCF-7, BT474,
MDA-MB231, MDA-MB231HM, SK, MDA-MB-435, MCF-10A and Hela
cells. B) The expression of DKK1 in MCF-7, BT474, MDA-MB231, MDA-
MB231HM, SK, MDA-MB-435, MCF-10A and Hela cells by western blot.
doi:10.1371/journal.pone.0037624.g001
Table 1. Clinical and histopathological features in 85 triple
negative patients.
Feature No. Rate(%)
Pathology type
IDC 63 74.12%
Other 22 25.88%
Lymph node status
0 54 63.53%
.=1 31 36.47%
Tumor size
,=2 cm 30 35.29%
.2 cm 55 64.71%
Tumor stage
Stage1,2 62 72.94%
Stage3 23 27.06%
Menopausal status
Pre 41 48.24%
Post 44 51.76%
TOTAL 85 100%
IDC, invasive ductal carcinoma;
doi:10.1371/journal.pone.0037624.t001
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Cell lysates were clarified by centrifuge at 10,000 g. Immuno-
blots were probed according to standard protocols with antibody
DKK-1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) and
beta-catenin (Abcam, Cambridge, MA, USA). The quality of
loading and transfer was assessed by immunostaning with
GAPDH antibody (Santa Cruz Biotechnology, Santa Cruz, CA,
USA). Immunoblots were developed by using enhanced chemi-
limminescent regent (Pierce ECL, Rockford, IL, USA) and images
were captured by the FUJIFILM LAS-3000 system (Fuji film,
Tokyo, Japan).
Immunohistochemistry
Tumor sections were subjected to immunohistochemical stain-
ing for DKK1 and beta-catenin. Antibodies used were polyclonal
DKK1 antibody (Santa Cruz Biotechnology, Santa Cruz, CA,
USA) and polyclonal beta-catenin antibody (Abcam, Cambridge,
MA, USA ). Tumor sections were incubated in a 1:50 dilution of
DKKA and a 1:1000 of beta-catenin at 4uC overnight. Primary
antibodies were detected by HRP-conjugated secondary antibod-
ies followed by colorimetric detection with 3,3-diaminobenzidine
(DAB).
Evaluation of Immunohistochemical Variables
Immunohistochemical staining results were assessed by two
pathologists independently with no knowledge of patient charac-
teristics. Discrepancies were resolved by consensus. DKK1
staining was evaluated using the following criteria: positive, dark
brown staining in .50% tumor cells completely obscuring
cytoplasm; and absent, no appreciable staining in tumor cells
[21]. For beta-catenin protein immunoreaction evaluation, we
considered more than 10% of cells exhibiting cytoplasmic/nuclear
staining as positive results [22].
Statistical Analysis
The follow-up period was defined as the time from surgery to
the last observation for censored cases or relapse/death for
complete observations. Relapses-free survival was defined as the
time between the date of the primary surgery to the date of relapse
or June 2011. Overall survival was defined as the time between the
date of the primary surgery to the date of death or June 2011.
Postoperative relapse-free survival probability and overall survival
probability were derived from the Kaplan-Meier estimate, and the
differences between survival curves were compared by means of
the logrank test. DKK-1 positive tumors were compared to DKK-
1 negative tumors for the same clusters, using the two sided Person
x
2 test. Statistics was analyzed using Stata/SE version 10.0 (Stata
Corporation, College Station, TX, USA). All P values are two-
sided and P,0.05 were considered significant.
Figure 2. Cytoplasmic immunostaining of DKK1 and beta-catenin in carcinomas. A) Positive immunostaining of DKK1 in an invasive ductal
breast carcinoma, 6400 magnification. B)Negative immunostaining of DKK1 in another invasive ductal breast carcinoma, 6400 magnification. C)
Positive immunostaining of beta-catenin in an invasive ductal breast carcinoma,6400 magnification. D) Negative immunostaining of beta-catenin in
another invasive ductal breast carcinoma, 6400 magnification.
doi:10.1371/journal.pone.0037624.g002
Table 2. Correlation between the expression of DKK1 and
beta-catenin.
DKK1(+) DKK1(-) Total
Beta-catenin(+) 44(51.76%) 11(12.94%) 55
Beta-catenin(-) 8(9.41%) 22(25.88%) 30
Total 52 33 85
X
2=23.25, P=0.000.
doi:10.1371/journal.pone.0037624.t002
DKK1, ßcatenin Expression in Breast Cancer Patients
PLoS ONE | www.plosone.org 3 May 2012 | Volume 7 | Issue 5 | e37624DKK1, ßcatenin Expression in Breast Cancer Patients
PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e37624Results
1. Expression of DKK1 in Breast Cell Lines
The levels of DKK1 mRNA in 6 different breast carcinoma cell
lines were compared with those in the normal MCF10A breast cell
line and in Hela cell line. The mRNA expression of DKK-1 in
MCF-7, SK, MDA-MB-435 and Hela cell lines were relatively
lower than those in BT474, MDA-MB231, MDA-MB231-HM
and MCF10A cells. We further investigated DKK1 protein
expression in these cells by western-blot. As shown in Figure 1,
high DKK1 protein expression was confirmed in hormone-
resistant breast cell lines MDA-MB231, MDA-MB231-HM,
MDA-MB-435 expect for SK. Interestingly,a very low expression
level of DKK1 was found in MCF-7 and BT474 cells, which were
both hormone sensitive. And a low amount of DKK1 was also
found in MCF10A cell.
2. Patient Characteristics
Next we investigated the relationship between DKK1 and beta-
catenin expression level in clinical breast cancer samples by
immunohistochemical staining. All of the tumor samples were
invasive breast carcinomas. Fifty of the cases had undergone
modified radical mastectomy, 29 radical mastectomy, and the
remaining 6 cases breast-conserving surgery. After the surgical
procedure, 72 patients received adjuvant systemic therapy
according to accepted practice guidelines. Chemotherapy only
was administered to 55 patients, 17 received radiotherapy after
chemotherapy, and 10 of the patients were given hormonal
therapy. The chemotherapy regimen for most of these patients was
mainly anthracycline based. Patient characteristics are presented
in Table 1. During the follow-up, 64 patients (75.29%) were
disease free without relapse or metastasis, 32 (37.65%) patients
developed recurrence or metastasis: 8 (9.41%) with local relapse
and 24 (28.24%) with bone or distant metastasis (liver, lung, brain)
and 17 (20.00%) patients of those died of breast cancer.
3. DKK1 and Beta-catenin Immunostaining
Representative images of DKK1 and beta-catenin were listed in
Figure 2. DKK1 staining was mainly observed in the cytoplasm of
tumor cells. Expression of DKK1 was found in 52 cases of all the
85 cases, negative expression was found in 33 cases. For the
cellular localization of beta-catenin by immunostaining, cytoplas-
mic/nuclear staining of beta-catenin was observed in 55 of 85
breast cancer patients, and no staining was observed in the other
30 cases. And there was a significant correlation between the
expression of DKK1 and beta-catenin (p=0.000). Details were
listed in Table 2.
4. Association of DKK1 and Beta-catenin with Clinical
Outcome in Triple Negative Patients
Using the logrank test, Figure 3A-B showed significant
differences in relapse-free survival curves and overall survival
curves according to DKK1 expression. Patients with negative
DKK1 expression had a better relapse free survival than those
with positive expression (84.8% vs 48.1%, P=0.000). Overall
survival difference was also observed between the DKK1 negative
and positive patients (71.2% vs 93.9%, P=0.004). Figure 3C-D
presented survival curves according to beta-catenin expression.
The relapse-free survival probability of beta-catenin negative
patients was better than beta-catenin positive patients (80% vs
52.7%, P=0.01). Statistical difference in overall survival was seen
between beta-catenin-negative and beta-catenin-positive patients
(93.3% vs 72.7%, P=0.012). Patients with either DKK1 negative
or beta-catenin negative had better relapse free survival than
patients with both DKK1 and beta-catenin positive expression
(78% vs 47.7%, P=0.001). Statistical difference was also observed
in overall survival (92.7% vs 68.2%, P=0.001).
5. Univariate and Multivariate Analysis of Prognostic
Factors and Adjuvant Treatments for Breast Cancer
Patients
Univariate analysis of relationships between tumor character-
istics and patients’ outcome indicated that lymph node status,
tumor stage, expression of DKK1 and beta-catenin were
significantly associated with relapse-free survival, whereas no
significant prognostic values were found with other factors listed in
Table 3. As for overall survival, tumor stage, DKK1 and beta-
catenin were found to have significant prognostic values while no
such correlation was found in other factors (Table 3). Cox’s
proportional-hazard regression model was used to determine
which factor was independently or jointly predicative of relapse-
Figure 3. Kaplan-Meier curves based on DKK1 and beta-catenin expression. A) B): Kaplan-Meier estimates for relapse-free survival and
overall survival based on DKK1 status. C) D): Kaplan-Meier estimates for relapse-free survival and overall survival based on beta-catenin status. E) F):
Kaplan-Meier estimates for relapse-free survival and overall survival based on DKK1 and beta-catenin status.
doi:10.1371/journal.pone.0037624.g003
Table 3. Univariate analysis of prognostic factors for breast
cancer patients.
Relapse-free Survival Overall Survival
RR(95%CI) P RR(95%CI) P
Pathology type 0.794(0.367–1.716) 0.557 0.624(0.231–1.688) 0.353
Lymph node status 2.294(1.139–4.621) 0.020 1.943(0.748–5.049) 0.173
Tumor size 1.651(0.763–3.570) 0.215 1.444(0.509–4.102) 0.490
Tumor stage 3.510(1.743–7.066) 0.000 3.369(1.289–8.807) 0.013
Menopausal status 1.772(0.866–3.626) 0.117 1.726(0.638–4.667) 0.282
dkk1 4.898(1.878–12.772) 0.001 7.104(1.595–31.642) 0.010
beta-catenin 3.035(1.246–7.389) 0.014 5.482(1.243–24.182) 0.025
doi:10.1371/journal.pone.0037624.t003
Table 4. Multivariate analysis of prognostic factors and
adjuvant treatments for breast cancer patients.
Relapse-free
Survival Overall Survival
RR(95%CI) P RR(95%CI) P
Lymph
node status
1.105
(0.433–2.820)
0.835 - -
Tumor
stage
2.539
(0.993–6.487)
0.052 2.773
(1.032–7.449)
0.043
dkk1 3.048
(1.060–8.765)
0.039 3.756
(0.780–18.077)
0.099
beta-
catenin
1.751
(0.664–4.617)
0.257 3.392
(0.708–16.245)
0.126
doi:10.1371/journal.pone.0037624.t004
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DKK1 to be an independent risk factor for relapse free survival
and tumor stage to be an independent risk factor for overall
survival (Table 4). We further tested the prognostic value of DKK1
in different tumor stage or lymph node status subgroups. We
found that in our study the DFS and OS of stage II DKK1
negative tumors was significantly higher than that of DKK1
positive tumors (DFS p=0.013; OS p=0.028). In the lymph node
negative group, DFS and OS of DKK1 positive patients was
significantly lower than that of DKK1 negative patients (DFS
p=0.002; OS p=0.023). Details were listed in Table 5.
6. Correlation of DKK1 and Beta-catenin Expression with
Other Clinical and Pathological Parameters
Table 6 listed the correlation of DKK1 and beta-catenin
expression with the tumor characteristic parameters. The expres-
sion of DKK1 was found associated with the lymph node status,
tumor stage and the expression of beta-catenin was associated with
pathology type. No significant association was found in other
tumor parameters.
Discussion
In this study we reported that DKK1 protein was expressed in
breast cancer hormone-resistant cell lines MDA-MB-231, MDA-
MB-231-HM and MDA-MB-435. Although DKK1 mRNA
expression was detected in receptor-positive or HER2-positive
breast cancer cells we studied, no such protein expression was
found in these cells. It is likely that most DKK1 has already been
secreted out of these cells and so no DKK1 can be detected in the
cells. Forget MA [19] has reported positive expression of DKK1 in
the supernatants of MCF-7 cells by ELISA.
We found patients with positive expression of DKK1 as well as
beta-catenin were associated with a poor outcome, meanwhile the
DFS and OS of stage II DKK1 negative tumors in our study was
significantly longer than that of DKK1 positive tumors(DFS
p=0.013; OS p=0.028). Therefore, it might be helpful to
integrate the DKK1 expression status with the tumor stage to
help predict the prognosis of triple negative breast cancers,
although the cases in other stages were too small to detect its
prognostic significance. Furthermore, in patients with no lymph
node metastasis, the DFS and OS of DKK1 positive patients was
significantly longer than that of DKK1 negative patients(DFS
p=0.002; OS p=0.023). Thus DKK1 expression might be helpful
to predict the prognosis of node-negative patients.
DKK1, which interacts with LPR6 of Wnt/beta-catenin
pathway, is regulated by progesterone in normal endometrical
stroma cells [23]. Consistent with our result, Forget MA [19] and
co-workers had also observed DKK1 in two hormone-indepen-
dent prostate cancer lines (DU45 and PC3) and hormone
receptor-negative breast tumor but not in a hormone-dependent
tumor (LNCaP). Up-regulation of DKK1 in our study correlated
with cytoplasmic/nuclear beta-catenin accumulation in triple
negative breast cancers (p=0.000). As DKK1 is a Wnt target
gene, this elevation may actually indicate the activation of pathway
activity.
The role of the Wnt/beta-catenin pathway activation in breast
cancer has been controversial. Beta-catenin plays significant roles
in the regulation of mammary development and tumorigenesis
through its association with E-cadherin in cell adhesion, regulation
Table 5. Prognostic value of DKK1 in stage II tumor, lymph
node negative subgroup.
OS
P(logrank
test) dfs
P(logrank
test)
01 01
Stage II DKK1+ 20 2 0.028 19 3 0.013
DKK12 21 7 16 12
Lymph node
negative
DKK1+ 22 2 0.023 22 2 0.002
DKK12 20 6 14 12
0: if event censored; 1: if event occurred.
doi:10.1371/journal.pone.0037624.t005
Table 6. Correlation of DKK1 and beta-catenin expression with other clinical and pathological parameters.
DKK1+ DKK1- X
2 P beta- catenin+ beta- catenin- X
2 P
Pathology type
IDC 37 26 1.204 0.273 45 18 4.817 0.028
Other 15 7 10 12
Lymph node status
0 26 24 4.305 0.038 31 19 0.389 0.533
.=1 26 9 24 11
Tumor size
,=2 cm 22 11 0.685 0.408 23 11 0.215 0.643
.2 c m 3 02 2 3 21 9
Tumor stage
Stage1,2=0 33 29 6.098 0.014 37 25 2.537 0.111
Stage 3=1 19 4 18 5
Menopausal status
Pre 25 16 0.001 0.971 24 17 1.320 0.251
P o s t 2 71 7 3 11 3
doi:10.1371/journal.pone.0037624.t006
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Lin SY and coworkers reported the nuclear staining of beta-
catenin was associated with poor outcome of breast cancer patients
[11]. However, several other studies failed to find such association
[24,25]. One possible explanation is these studies did not
categorize the beta-catenin localization by molecular subtypes.
Khramtsov AI and colleagues previously reported that Wnt/beta-
catenin pathway activation was enriched in basal-like breast
cancers [13]. There are significant limitations to this current study,
including the small data set, few cases of stage I patients, no
validation in an independent series of cases, categorize the
accumulation of DKK1 and beta-catenin in breast cancers by
immunohistochemical to positive and negative rather than scoring.
Despite these shortcomings, our results do support the idea that
Wnt/beta-catenin signaling pathway is activated in triple negative
breast cancers.
Although triple negative breast cancers only account for 15–
20% of all breast cancers, it represents an important clinical
challenge since no endocrine therapy or targeted agents are
available. Current treatment strategies for it include many
chemotherapy agents. Comparing with luminal As or Bs, there
is a markedly higher response rate to chemotherapy in this
subtype. However, the disease-free survival and over-all survival of
triple negative breast cancers are far shorter. Our data indicated
that beta-catenin might be a potential therapeutic target of this
subtype. Effects of Wnt pathway inhibitors have been tested in
colorectal cancer [26,27], further investigation of such compounds
are necessary to be carried out in vitro and in vivo to explore their
potential therapeutic effects in triple negative breast cancers.
In conclusion, accumulation of DKK1 and cytoplasmic/nuclear
beta-catenin in triple negative cancers indicate poor outcome of
patients. DKK1 might be a valuable biomarker in predicting the
prognosis of patients with earlier stage or no lymph node
metastasis. DKK1 alone or together with beta-catenin might be
helpful in identifying patients who might benefit from early
systemic treatment. The potential mechanism between increased
DKK1 expression and Wnt/beta-catenin pathway activation and
the mechanism by which the Wnt/beta-catenin pathway is
activated in triple negative cancers is still unknown. It is possible
that through further understanding of the role of Wnt/beta-
catenin pathway activation, beta-catenin would be a potential
therapeutic target for the triple negative breast cancer.
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